Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 92,524,848
  • Shares Outstanding, K 1,639,930
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.17
  • Price/Sales 4.79
  • Price/Cash Flow 18.49
  • Price/Book 6.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.06 +8.37%
on 07/27/17
57.99 -2.72%
on 08/15/17
+1.68 (+3.07%)
since 07/18/17
3-Month
51.56 +9.43%
on 06/07/17
57.99 -2.72%
on 08/15/17
+2.64 (+4.91%)
since 05/18/17
52-Week
46.01 +22.63%
on 01/26/17
60.45 -6.67%
on 01/10/17
-2.26 (-3.85%)
since 08/18/16

Most Recent Stories

More News
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

MRK : 61.49 (-0.57%)
ABBV : 69.96 (+0.16%)
GILD : 72.11 (-0.32%)
BMY : 56.42 (-0.62%)
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo

Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.

MYL : 30.72 (+0.52%)
AZN : 29.12 (+0.14%)
MRK : 61.49 (-0.57%)
NVS : 82.76 (-0.50%)
PFE : 32.67 (-0.85%)
GSK : 38.75 (-0.77%)
BMY : 56.42 (-0.62%)
Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017

--Analyses from the ACROPOLIS(TM) Global Real-World Data Program Provide Insight into the Anticoagulation of a Broad Range of NVAF Patients at Risk for Stroke

PFE : 32.67 (-0.85%)
BMY : 56.42 (-0.62%)
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.

EXEL : 26.33 (-2.05%)
RHHBY : 31.2300 (-0.98%)
PFE : 32.67 (-0.85%)
BMY : 56.42 (-0.62%)
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa

FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.

JNJ : 132.63 (-0.31%)
ACAD : 31.08 (+0.16%)
PTLA : 53.99 (+1.45%)
BMY : 56.42 (-0.62%)
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

AZN : 29.12 (+0.14%)
MRK : 61.49 (-0.57%)
RHHBY : 31.2300 (-0.98%)
BMY : 56.42 (-0.62%)
Next Support Level for Bristol-Myer Sqb (BMY) is $57.29

Shares of Bristol-Myer Sqb (NYSE:BMY) have bearishly opened below the pivot of $57.79 today and have reached the first support level of $57.58. Should the shares continue to fall, the support pivots of...

BMY : 56.42 (-0.62%)
Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

--Co-Primary Endpoint of Progression-Free Survival Favored the combination of Opdivo and Yervoy vs. sunitinib but did not Reach Statistical Significance

BMY : 56.42 (-0.62%)
Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses

Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.

CLVS : 71.96 (+2.99%)
TSRO : 113.86 (+4.41%)
PFE : 32.67 (-0.85%)
BMY : 56.42 (-0.62%)
Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

MRK : 61.49 (-0.57%)
ABBV : 69.96 (+0.16%)
GILD : 72.11 (-0.32%)
BMY : 56.42 (-0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 57.12
1st Resistance Point 56.77
Last Price 56.42
1st Support Level 56.24
2nd Support Level 56.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.